Alembic Pharmaceuticals is currently trading at Rs. 765.55, up by 19.60 points or 2.69% from its previous closing of Rs. 745.95 on the BSE.
The scrip opened at Rs. 746.00 and has touched a high and low of Rs. 775.00 and Rs. 732.00 respectively. So far 10883 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 840.95 on 28-Apr-2020 and a 52 week low of Rs. 435.10 on 21-Jun-2019.
Last one week high and low of the scrip stood at Rs. 840.95 and Rs. 729.20 respectively. The current market cap of the company is Rs. 14525.15 crore.
The promoters holding in the company stood at 72.97%, while Institutions and Non-Institutions held 15.96% and 11.07% respectively.
The US Food & Drug Administration (USFDA) has classified the Alembic Pharmaceuticals’ General Oral Solid Formulation Facility located at Panelav as Voluntary Action Indicated (VAI). Inspection at the said facility was conducted by USFDA from March 09, 2020 to March 13, 2020.
VAI means USFDA accepted the company’s response to its observations.
Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.